Townsend Richard Nolan reported grant involving 2,306 shares of Lexeo Therapeutics, Inc. at $2.64 for $6.10k on Sep 14, 2026

Grant
Form 4 code A. Grant, award, or other acquisition under Rule 16b-3(d).
Chief Executive Officer
Chief Executive Officer
Filed Sep 28, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
$6,097.06Shares × reported price
Shares traded
2,306Common Stock
Price per share
$2.64Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
376,778Direct
Trade date
Sep 14, 2026Grant
Filed
Sep 28, 2026, 5:15 PM ET14-day reporting delay
Accession
0001995218-26-000017Code A · Transaction 230538
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 24, 2026Grant145,500$0.00$0Trade 230539
2 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 14 calendar days after the transaction date.

LXEO price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
LXEO · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +54%1w ago +56%1d ago +35%
Returns since7d +8.6%30d −0.3%90d180d1y

Footnotes in full

F1: The reporting person is voluntarily reporting the acquisition of shares of the Issuer's common stock pursuant to the Lexeo Therapeutics, Inc. 2023 Employee Stock Purchase Plan. This transaction is exempt under both Rule 16b-3(c) and Rule 16b-3(d). F2: Includes 242,911 Restricted Stock Units. F3: 25% of the shares underlying the option vest and become exercisable on September 24, 2027, and 1/48th of the shares underlying the option shall vest in monthly installments thereafter, subject to the Reporting Person's continuous service.